Simvastatin does not improve outcomes in patients critically ill with COVID-19

1. In this randomized controlled trial, high-dose simvastatin did not reduce the need for organ support among critically ill patients with coronavirus disease 2019 (COVID-19). 2. High-dose simvastatin was associated with increased rates of serious adverse events amongst critically ill patients with COVID-19. Evidence Rating Level: 1 (Excellent) Study Rundown: Among critically ill patients who […]

The post Simvastatin does not improve outcomes in patients critically ill with COVID-19 first appeared on 2 Minute Medicine.